Catalyst Biosciences Inc. (NASDAQ:CBIO) has a beta value of 0.93 and has seen 1.51 million shares traded in the last trading session. The company, currently valued at $9.51M, closed the last trade at $0.27 per share which meant 1.28% during that session. The CBIO stock price is -48.15% off its 52-week high price of $0.40 and 77.78% above the 52-week low of $0.06. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.86 million shares traded. The 3-month trading volume is 965.22K shares.
The consensus among analysts is that Catalyst Biosciences Inc. (CBIO) is a Hold stock at the moment, with a recommendation rating of 2.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 2 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.1.
Catalyst Biosciences Inc. (NASDAQ:CBIO) trade information
Sporting 1.28% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, 01/23/23 when the CBIO stock price touched $0.27 or saw a rise of 4.63%. Year-to-date, Catalyst Biosciences Inc. shares have moved -17.32%, while the 5-day performance has seen it change 2.86%. Over the past 30 days, the shares of Catalyst Biosciences Inc. (NASDAQ:CBIO) have changed -12.07%. Short interest in the company has seen 0.53 million shares shorted with days to cover at 0.49.
Wall Street analysts have a consensus price target for the stock at $3.00, which means that the shares’ value could jump 91.0% from current levels. The projected low price target is $3.00 while the price target rests at a high of $3.00. In that case, then, we find that the current price level is -1011.11% off the targeted high while a plunge would see the stock gain -1011.11% from current levels.
Catalyst Biosciences Inc. (CBIO) estimates and forecasts
Figures show that Catalyst Biosciences Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -5.19% over the past 6 months, with this year growth rate of 131.36%, compared to 4.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 87.50% and 87.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be -89.20%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 33.30% over the past 5 years.
Catalyst Biosciences Inc. is expected to release its next earnings report between March 29 and April 03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Catalyst Biosciences Inc. (NASDAQ:CBIO)’s Major holders
Insiders own 11.36% of the company shares, while shares held by institutions stand at 25.99% with a share float percentage of 29.32%. Investors are also buoyed by the number of investors in a company, with Catalyst Biosciences Inc. having a total of 45 institutions that hold shares in the company. The top two institutional holders are Nantahala Capital Management, LLC with over 2.76 million shares worth more than $4.91 million. As of Jun 29, 2022, Nantahala Capital Management, LLC held 8.76% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 1.37 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $2.44 million and represent 4.36% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 29, 2022, the former fund manager holds about 2.63% shares in the company for having 0.83 million shares of worth $1.47 million while later fund manager owns 0.51 million shares of worth $0.91 million as of Jun 29, 2022, which makes it owner of about 1.63% of company’s outstanding stock.